ORCHID was a multicenter, blinded, placebo-controlled randomized trial conducted at 34 hospitals in the US between April 2 and June 19, 2020. Adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infection were enrolled, with the last outcome assessment on July 17, 2020. The planned sample size was 510 patients with five interim analyses; however, the trial was stopped at the fourth interim analysis for futility with a sample size of 479 patients.The distribution of the day 14 clinical status score (measured using a 7-category ordinal scale) was not significantly different for patients randomized to receive hydroxychloroquine compared with placebo.Instructions for requesting individual-level data are available on BioData Catalyst at <a href="https://biodatacatalyst.nhlbi.nih.gov/resources/data/">https://biodatacatalyst.nhlbi.nih.gov/resources/data/</a>. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at <a href="https://biodatacatalyst.nhlbi.nih.gov/contact">https://biodatacatalyst.nhlbi.nih.gov/contact</a>.

PETAL Network: Outcomes Related to COVID-19 Treated With    Hydroxychloroquine Among Inpatients With Symptomatic Disease (ORCHID)    Trial

Variables — phs002299 — PETAL Network: Outcomes Related to COVID-19 Treated With    Hydroxychloroquine Among Inpatients With Symptomatic Disease (ORCHID)    Trial

PETAL Network: Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among Inpatients With Symptomatic Disease (ORCHID) Trial

Other (4)